Knight Therapeutics Inc (GUD) Price Target Raised to C$11.00
Knight Therapeutics Inc (TSE:GUD) had its price objective upped by TD Securities from C$10.00 to C$11.00 in a report issued on Friday morning, StockTargetPrices.com reports. TD Securities currently has a buy rating on the stock.
Other equities research analysts have also issued research reports about the stock. CIBC lifted their target price on shares of Knight Therapeutics from C$9.50 to C$9.80 in a research note on Friday, November 11th. Scotiabank reduced their price objective on shares of Knight Therapeutics from C$10.00 to C$9.50 and set an outperform rating for the company in a research note on Friday, November 11th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Knight Therapeutics currently has a consensus rating of Buy and an average target price of C$9.83.
Knight Therapeutics (TSE:GUD) opened at 9.78 on Friday. Knight Therapeutics has a 1-year low of $5.89 and a 1-year high of $9.86. The company has a 50-day moving average price of $9.20 and a 200-day moving average price of $8.65. The firm has a market capitalization of $1.30 billion and a P/E ratio of 68.87.
About Knight Therapeutics
Knight Therapeutics Inc is a Canada-based pharmaceutical company. The Company is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices in Canada and select international markets. It finances other life sciences companies in Canada and internationally.
Receive News & Stock Ratings for Knight Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics Inc and related stocks with our FREE daily email newsletter.